Cite
HARVARD Citation
Izumi, N. et al. (n.d.). IDDF2018-ABS-0110 Efficacy and safety of SOFOSBUVIR/VELPATASVIR plus RIBAVIRIN for 12 or 24 weeks in genotype 1 or 2 HCV-INFECTED japanese patients with prior treatment failure to daa-based regimens. Gut. p. A99. [Online].